DRIEHAUS CAPITAL MANAGEMENT LLCDRIEHAUS CAPITAL MANAGEMENT LLC

Institutional investor · Portfolio as of Q2 2023

SEC EDGAR SourceSEC Filings

Top Holdings380 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

3.4M$341.1M4.3%$56.15+72.68%
18 qtrssince 2019-Q1
Decreased
0

XENON PHARMACEUTICALS INC

4.8M$183.3M2.3%$26.71+43.88%
14 qtrssince 2020-Q1
Increased
53

AXCELIS TECHNOLOGIES INC

746,503$136.9M1.7%$67.98+163.35%
10 qtrssince 2021-Q1
Increased
49

CAMECO CORP

4.2M$130.8M1.7%$26.51+15.79%
8 qtrssince 2021-Q3
Increased
69
513,799$128.1M1.6%
3 qtrssince 2022-Q4
Decreased
0
IBNIBN
ADR

ICICI BANK LTD-SPON ADR

5.2M$120.8M1.5%$15.50+45.32%
18 qtrssince 2019-Q1
Increased
48

INSPIRE MED SYS INC

353,449$114.7M1.4%$185.12+72.43%
18 qtrssince 2019-Q1
Increased
49

e.l.f. Beauty, Inc.

891,025$101.8M1.3%$34.39+227.17%
6 qtrssince 2022-Q1
Decreased
0

TransMedics Group, Inc.

1.2M$97.6M1.2%$41.76+102.55%
5 qtrssince 2022-Q2
Increased
51

ATI INC

2.2M$95.6M1.2%$26.60+66.26%
6 qtrssince 2022-Q1
Decreased
0

CRINETICS PHARMACEUTICALS IN

5.3M$95.5M1.2%$20.83-14.51%
13 qtrssince 2020-Q2
Increased
47

KINSALE CAP GROUP INC

254,350$95.2M1.2%$236.10+56.98%
7 qtrssince 2021-Q4
Increased
49

CELSIUS HOLDINGS INC

636,593$95M1.2%$20.02+147.83%
13 qtrssince 2020-Q2
Increased
56
DICEDICEDelisted

DICE THERAPEUTICS INC

2M$94.7M1.2%
8 qtrssince 2021-Q3
Increased
48

INSTALLED BLDG PRODS INC

540,850$75.8M1.0%$117.36+14.26%
2 qtrssince 2023-Q1
Increased
62

MONDAY COM LTD

429,814$73.6M0.9%$149.35+13.23%
2 qtrssince 2023-Q1
Increased
61

AXON ENTERPRISE INC

347,728$67.8M0.9%$155.92+25.14%
15 qtrssince 2019-Q4
Decreased
0

FTAI AVIATION LTD

2.1M$65.8M0.8%$26.87+12.60%
2 qtrssince 2023-Q1
Increased
47
TCOMTCOM
ADR

TRIP.COM GROUP LTD-ADR

1.9M$65.7M0.8%$28.37+21.62%
5 qtrssince 2022-Q2
Increased
42

SAIA INC

187,829$64.3M0.8%$235.20+47.45%
3 qtrssince 2022-Q4
Increased
43
$7.9B
AUM
380
Positions
Q2 2023
Filing
Rating · 2.0
Quarterly Portfolio Change
-17%Q1'22$8.1B-24%Q2'22$6.2B+7%Q3'22$6.6B+2%Q4'22$6.7B+6%Q1'23$7.1B+11%Q2'23$7.9B
Activity profile
$ moved · Q2'23
New23%Increased34%Decreased18%Exited25%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.2 years
<1Q12%1-4Q18%1-2Y16%2Y+54%

DRIEHAUS CAPITAL MANAGEMENT LLC manages $7.9B across 380 positions as of Q2 2023. Top holdings: TSM (4.3%), XENE (2.3%), ACLS (1.7%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.

Q2 2023 Summary

Active quarter - 112 new positions, 110 exits, 157 increased. Top move: CCJ (INCREASED, conviction 69). Portfolio: $7.9B across 380 positions.

Top holdings by portfolio weight

Total AUM$8B
TSM4.31%
XENE2.31%
ACLS1.73%
CCJ1.65%
MS51.62%
IBN1.53%
INSP1.45%
ELF1.29%
TMDX1.23%
ATI1.21%
Other1.21%

Portfolio allocation by GICS sector

Sectors11
Technology20.59%
Industrials19.79%
Healthcare17.84%
Unknown12.03%
Consumer Cyclical10.29%
Consumer Defensive5.43%
Financial Services5.25%
Energy3.61%
Communication Services2.62%
Basic Materials2.19%
Other0.37%

Behavioral investing profile

Checking access…
Momentum Trader- primarily Technology, Industrials, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record66
Conviction43
Concentration25
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
EWTXEWTXEDGEWISE THERAPEUTICS INC
Q2 2025 Q2 2026+3.4M shares+$161.9M
5Q
IMAXIMAXIMAX CORP
Q2 2025 Q2 2026+1.9M shares+$82.1M
4Q
IMNMIMNMIMMUNOME INC
Q3 2025 Q2 2026+4.1M shares+$90M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used